PCI Biotech - Småprat 2019 (PCIB)

[Biotop20]

Riktig. Omsatt 37,3k aksjer i dag. Vitner ikke akkurat om at BP er på kjøper’n. Mye taler for at enkelte folk her inne fant opp kruttet før Alfred Nobel. Er komfortabel med min beholdning, men ser pt ingen grunn til å kjøpe flere aksjer i selskapet nå

[anon58924711]

Nå er det lite trolig at BP kommer krypende inn på aksjonærlisten ved å kjøpe opp litt hist og pist midt i den roligste perioden på året. Man trenger ikke å ha funnet opp kruttet for å konkludere med at det er lite trolig at verdens største farmasøytiske selskaper kommer seilende inn og blir synlige i aksjonærregisteret i det hele tatt. Hva enn BP foretar seg, så vil det antagelig ikke forløpe seg ved at Novartis eller Roche plutselig vaker rolig rundt på topp 300 i Pcib i løpet av et par stille sommeruker. Det hadde fungert som dynamitt på kursen, og såpass mye vet BP’s M&A avdelinger om sprengstoff at det vil de sikkert forsøke å unngå.

[abacus]

Riktig. Omsatt 37,3k aksjer i dag. Vitner ikke akkurat om at BP er på kjøper’n.

Om noen av de største farmasiselskapene i verden skulle begynne å kjøpe aksjer i PCI Biotech, ville det være svært oppsiktsvekkende - og i så fall lukte av fiendtlig oppkjøp. Det scenariet tror jeg vi kan se bort fra.

Hvor Alfred Nobel kommer inn her, skjønte jeg ikke. For øvrig ble kruttet oppfunnet i Kina, trolig om lag 1 100 år før Alfred Nobel fant opp dynamitten.

[Otard]

Kinaputter ja🤭 dynamitt er no anna🤣

[Chilli]

Ny uke og nye muligheter​:star_struck:
Uannsett, nyyt ferien😎

[Lothian]

Der kom extention på 6 mnd. OK da.

[Don_suger]

Fan, da ble det “bare” en forlengelse…

[thosolb]

Men les hele da. Neste år skal de bruke på å diskutere eventuelt partnerskap.

thereafter use the following 6 months (until end June 2020) to evaluate the
potential for a further partnership

[Lothian]

Men siste setning peker på mulig utvidet samarbeid…

[Don_suger]

Ja, ser at del ligger en endring i teksten men da må vi da vente i minst 1 år på å komme oss til klinisk…

De har bestandig hatt med følgende tekst “The companies will evaluate the data
generated in this collaboration and explore the potential for a further
partnership based on this outcome.”

Så “further partnership” er ikke ny, desverre…

[Smerdrim]

Hvis vi kommer til juni 2020, og det ikke blir klinisk, da skjønner jeg ingen ting. Brukt så mange år på å teste synergier, så må vel klinisk avtale være nærmest bankers nå?

[Bonusfrelst]

Hva skal en si. TTT i denne bransjen. Uansett positivt at det samarbeides tenker jeg

[Lothian]

Nok en gang en bekrefelse på at TTT.

Og nok en gang en bekreftelse på at mange her inne er altfor optimistiske. Var det 45% sjanse for en avtale om klinisk med upfront betaling etc noen her inne mente?

Så var det bare topp10 eller PCIB som måtte ha en uke ekstra for å finne ut om det var verdt å fortsette samarbeidet…

[anon44025098]

Få håpe at andre FimaNac samarbeidpartnere ikke trenger like langt tid

[Jubel]

PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company

Oslo (Norway), 22 July 2019 - PCI Biotech (OSE: PCIB), a cancer focused
biopharmaceutical company today announced that they are extending the
preclinical research collaboration with an undisclosed top-10 pharma company.
The pharma company is one of the global leaders in nucleic acid therapeutics and
the collaboration was initiated in September 2015.

The aim of the extension is to further evaluate the synergistic effects of both
parties’ technology platforms in an in vivo setting and to determine whether PCI
Biotech’s fimaNAc technology has the potential to enhance the therapeutic effect
of the partner’s nucleic acid therapeutic compounds. The research collaboration
is extended with 6 months until the end of 2019 and the companies have agreed to
thereafter use the following 6 months (until end June 2020) to evaluate the
potential for a further partnership.

PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company

Oslo (Norway), 18 December 2018 - PCI Biotech (OSE: PCIB), a cancer focused
biopharmaceutical company today announced that they are extending the
preclinical research collaboration with an undisclosed top-10 pharma company,
initiated in September 2015. The extended evaluation period spans over 6 months,
until the end of June 2019, and may be further extended.

The pharma company is one of the global leaders in nucleic acid therapeutics.
The aim of the extension is to further evaluate the synergistic effects of both
parties’ technology platforms and to determine whether PCI Biotech’s fimaNAc
technology has the potential to enhance the therapeutic effect of the partner’s
nucleic acid therapeutic compounds. The companies will evaluate the data
generated in this collaboration and explore the potential for a further
partnership based on this outcome.

[TekBot]

PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company

Oslo (Norway), 22 July 2019 - PCI Biotech (OSE: PCIB), a cancer focused
biopharmaceutical company today announced that they are extending the
preclinical research collaboration with an undisclosed top-10 pharma company.
…

Vis børsmeldingen

The pharma company is one of the global leaders in nucleic acid therapeutics and
the collaboration was initiated in September 2015.

The aim of the extension is to further evaluate the synergistic effects of both
parties’ technology platforms in an in vivo setting and to determine whether PCI
Biotech’s fimaNAc technology has the potential to enhance the therapeutic effect
of the partner’s nucleic acid therapeutic compounds. The research collaboration
is extended with 6 months until the end of 2019 and the companies have agreed to
thereafter use the following 6 months (until end June 2020) to evaluate the
potential for a further partnership.

Contact information:
Per Walday, CEO
pw@pcibiotech.no (mailto:pw@pcibiotech.no)
Mobile: +47 917 93 429

About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and
commercialisation of novel therapies for the treatment of cancer through its
innovative photochemical internalisation (PCI) technology platform. PCI is
applied to three distinct anticancer paradigms: fimaChem (enhancement of
chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction
technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics
delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company’s lead programme fimaChem consists of a pivotal study in bile duct
cancer, an orphan indication with a high unmet need and without approved
products. fimaVacc applies a unique mode of action to enhance the essential
cytotoxic effect of therapeutic cancer vaccines, which works in synergy with
several other state-of-the-art vaccination technologies. fimaNAc utilises the
endosomal release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks
facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com
(http://www.pcibiotech.com)

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Kilde

[Jubel]

Det er en viktig endring som dere ser mot forrige BP melding:

«The research collaboration
is extended with 6 months until the end of 2019 and the companies have agreed to
thereafter use the following 6 months (until end June 2020) to evaluate the
potential for a further partnership.»

Det er nå en helt klar plan for de siste 6 mnd med evaluering partnersamarbeid! Synes dette var meget bra presisering fra PCIB og BP TOP 10. Det er gode resultater som er oppnådd hvis ikke hadde det vært avsluttet nå! Så blir spørsmålet om BP vil betale/kjøpe teknologi, upfront, royalties, struktur, eierskap % osv.

De som investerer i bransjen vet dette er en god melding! En liten biotekmygg har fått BP TOP 10 på «kroken» til å helt klart vurdere med klar deadline partnership!

[Shqipe]

The research collaboration
is extended with 6 months until the end of 2019 and the companies have agreed to
thereafter use the following 6 months (until end June 2020) to evaluate the
potential for a further partnership.

Dette betyr jo “NESTE GANG VI SKAL FORNYE BLIR DET NOE ANNET ELLER INGENTING, ALTSÅ DEADLINE”

[Lothian]

Det er nok korrekt og kanskje er det PCIB som presser litt?

Det blir uansett himmel eller helvete med topp10 innen 1 år, får vi tro.

[Investor]

Oppfatter det som at Pcib setter en strek i sanden 30. Juni 2020 og sier til top 10 “vil dere være med videre etter det vil vi ha noe mer enn dette forskningsamssarbeidet.”